SecBot SecBot
8-K ·Filed May 21, 2026

OLMA

Olema Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001193125-26-234848
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

Monitor the full ASCO poster on May 30 for additional efficacy details and dose expansion data. Positive early signals could support partnership interest or pipeline valuation, but the small sample size warrants caution until larger cohorts confirm.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.68
T+0 close · May 21, 2026 · via day close
Latest settled
−22.15%
T+60 · $10.65
Vs SPY
−25.34%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 22 $13.68entry
  2. T+1 · 6mo ago −0.95%α −1.54% · $13.55
  3. T+5 · 6mo ago −7.09%α −8.75% · $12.71
  4. T+20 · 5mo ago −25.51%α −24.10% · $10.19
  5. T+60 · 3mo ago −22.15%α −25.34% · $10.65

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Olema Pharmaceuticals announced preliminary Phase 1 data for OP-3136, a KAT6 inhibitor, showing acceptable tolerability, target engagement, and early anti-tumor activity (3 partial responses in 19 evaluable patients) in heavily pretreated advanced solid tumors. The data will be presented at ASCO 2026 on May 30. This early clinical signal supports continued development but remains preliminary.

Key Facts

  • No dose-limiting toxicities observed up to 45 mg daily; no treatment discontinuations due to TRAEs.
  • Among 19 evaluable patients, tumor shrinkage in 13, with 2 confirmed and 1 unconfirmed partial response.
  • OP-3136 demonstrated sustained reduction in H3K23 acetylation, confirming on-target KAT6 inhibition.
  • Data to be presented at ASCO 2026 (May 30) and Phase 1 dose expansion ongoing.
  • The company also will present a trial-in-progress for Phase 3 OPERA-02 (palazestrant + ribociclib) at ASCO.

Financial Impact

No financial figures disclosed; early clinical data may increase probability of success for OP-3136 pipeline value.

Risk Factors

  • Phase 1 data is preliminary with small sample size (19 evaluable); response rates may not be durable or reproducible in larger groups.
  • Common grade 3 TRAEs (anemia 6%, neutropenia 28%) may limit tolerability at higher doses or in combination.
  • No control arm; efficacy signals need confirmation in randomized expansion.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-234848
Document: olma-ex99_1.htm0001193125-26-234848
Document: 0001193125-26-234848-index-headers.html0001193125-26-234848
Document: 0001193125-26-234848-index.html0001193125-26-234848
Document: 0001193125-26-234848.txt0001193125-26-234848

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 21, 2026